Cargando…
A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib
Sunitinib is an oral tyrosine kinase inhibitor (TKI) commonly used in the treatment of renal cell carcinoma (RCC). Among a broad range of toxicities, anemia and macrocytosis are common in patients treated with sunitinib. Correlation between sunitinib-associated macrocytosis and cobalamin deficiency...
Autores principales: | Reed, Jarred P, Chung, Joan, Banerjee, Natasha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538120/ https://www.ncbi.nlm.nih.gov/pubmed/31183290 http://dx.doi.org/10.7759/cureus.4310 |
Ejemplares similares
-
Macrocytic Anemia and Thrombocytopenia Induced by Orlistat
por: Palacios-Martinez, David, et al.
Publicado: (2013) -
Diagnosis and treatment of macrocytic anemias in adults
por: Nagao, Takayo, et al.
Publicado: (2017) -
Middle Eastern Adolescent With Macrocytic Anemia
por: Butala, Sneha, et al.
Publicado: (2017) -
Flow cytometry-detected changes in megaloblastic anemia secondary to cobalamin deficiency
por: Briones, Vania, et al.
Publicado: (2023) -
Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)